Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of once-weekly survodutide in compensated NASH/MASH cirrhosis
jRCT2031240541Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2024
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial in Cirrhosis and cirrhosis due to nonalcoholic steatohepatitis comparing Survodutide arm with Placebo arm (2 arms). Primary endpoint: Composite clinical endpoint (time to first event). Started Dec 2024; status: recruiting.
02
Drugs
03
Conditions
Cirrhosiscirrhosis due to nonalcoholic steatohepatitis
Beyond the preview
Go deeper on jRCT2031240541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240541.